Reports Q2 revenue $2.53B, consensus $2.49B. “In the second quarter, we achieved our ninth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health (BHC), excluding Bausch + Lomb. This consistent performance highlights our operational excellence and the strength of our diverse portfolio across therapeutic areas and geographies. As we look toward the second half of 2025, we remain focused on executing against our strategic priorities to drive continued growth and unlock long-term value for our shareholders,” said Thomas Appio, CEO, Bausch Health.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health to acquire Durect for $1.75 per share in cash upfront
- Bausch Health to acquire Durect for $1.75 per share in an all-cash transaction
- Bausch Health to reduce debt by $900M using cash on hand
- Bausch Health appoints Michael Goettler, Sandra Leung to board
- Bausch Health Canada announces CABTREO availability via public drug plans